ASN007

ASN007 is a preclinical-stage small molecule drug candidate being developed by Auson Pharmaceuticals for the treatment of chronic hepatitis B in adults and adolescents. The drug is characterized by an innovative once-weekly formulation, which is designed to improve patient adherence compared to the standard once-daily dosing regimens typically used for hepatitis B. ASN007 is part of Auson's pipeline focusing on infectious diseases and digestive system disorders. While specific biological targets and mechanisms of action have not been publicly disclosed, the candidate represents a formulation-driven approach to optimizing chronic hepatitis B therapy.